Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2759 | PEP flute Wiki | 0.50 |
| drug986 | Combined ART/hydroxychloroquine Wiki | 0.50 |
| drug4252 | Vitamin D 1000 IU Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D058345 | Asymptomatic Infections NIH | 0.71 |
| D058070 | Asymptomatic Diseases NIH | 0.29 |
| D014808 | Vitamin D Deficiency NIH | 0.18 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0100512 | Low levels of vitamin D HPO | 0.18 |
| HP:0011947 | Respiratory tract infection HPO | 0.08 |
Navigate: Correlations HPO
There are 4 clinical trials
The present study aims to assess the determinants of health-related quality of life and patient-centered long-term outcomes among survivors of hospitalization for Covid-19 in Brazil. The investigators will conduct a multicenter prospective cohort study nested in randomized clinical trials (coalition Covid-19 Brazil initiative) originally designed to assess the effects of specific Covid-19 treatments. Adult survivors of hospitalization due to proven or suspected SARS-CoV-2 infection will be followed up for a period of one year by means of structured telephone interviews. The primary outcome is one-year health-related quality of life assessed by the EQ-5D-3L. Secondary outcomes include all-cause mortality, rehospitalizations, return to work or study, physical functional status assessed by the Lawton & Brody Instrumental Activities of Daily Living Scale, dyspnea assessed by the modified medical research council dyspnea scale, need of long-term ventilatory support, symptoms of anxiety and depression assessed by the Hospital Anxiety and Depression Scale, and symptoms of posttraumatic stress disorder assessed by the Impact of Event Scale-revised. Four sets of variables (1-demographic characteristics, 2-pre-morbid state of health, 3-characteristics of acute illness, and 4- specific Covid-19 treatments received) will be assessed as potential risk factors for health-related quality of life and secondary outcomes.
Description: The outcome will be assessed using the Brazilian version of the Euroqol-5D-3L (EQ-5D3L) questionnaire. The utility score derived from the EQ5D-3L ranges from 0 (death) to 1 (perfect health).
Measure: One-year utility score of health-related quality of life Time: The outcome will be assessed 12 months after enrollment.Description: Incidence of all-cause mortality.
Measure: Incidence of all-cause mortality Time: The outcome will be assessed 3, 6, 9 and 12 months after enrollment.Description: Incidence of all-cause rehospitalizations.
Measure: Incidence of rehospitalizations Time: The outcome will be assessed 3, 6, 9 and 12 months after enrollment.Description: Percentage of return to work or study among patients that were working or studying at the moment of hospitalization.
Measure: Percentage of return to work or study Time: The outcome will be assessed 3, 6, 9 and 12 months after enrollment.Description: The outcome will be assessed using the Lawton & Brody Instrumental Activities of Daily Living Scale (the score ranges from 0 to 8, with higher scores indicating less dependence).
Measure: Score of Instrumental Activities of Daily Living Time: The outcome will be assessed 3, 6, 9 and 12 months after enrollment.Description: The outcome will be assessed using the modified medical research council dyspnea scale. Scores ranges from 0 to 4, with higher scores indicating worse symptoms.
Measure: Score of dyspnea Time: The outcome will be assessed 3, 6, 9, and 12 months after enrollment.Description: Percentage of patients requiring oxygen therapy, non-invasive ventilation, or mechanical ventilation.
Measure: Percentage of long-term ventilatory support need Time: The outcome will be assessed 3, 6, 9 and 12 months after enrollment.Description: The outcome will be assessed using the Hospital Anxiety and Depression Scale (anxiety and depression scores range from 0 to 21, with higher scores indicating worse symptoms).
Measure: Symptoms of anxiety and depression Time: The outcome will be assessed 3, 6, 9 and 12 months after enrollment.Description: The outcome will be assessed using the Impact Event Scale-Revised (the score ranges from 0 to 88, with higher scores indicating worse symptoms).
Measure: Symptoms of posttraumatic stress disorder Time: The outcome will be assessed 3, 6, 9 and 12 months after enrollment.Description: The outcome will be assessed using the Brazilian version of the Euroqol-5D-3L (EQ-5D3L) questionnaire. The utility score derived from the EQ5D-3L ranges from 0 (death) to 1 (perfect health).
Measure: Utility score of health-related quality of life at 3, 6, and 9 months Time: The outcome will be assessed 3, 6, and 9 months after enrollment.Description: The outcome will be assessed using the visual analogue scale of the Brazilian version of the Euroqol-5D-3L questionnaire (EQ-VAS; score range from o to 100, with higher scores indicating better self-rated health).
Measure: Score of self-rated health Time: The outcome will be assessed 3, 6, 9, and 12 months after enrollment.The Canadian Paediatric Society recommends breastfeeding during COVID-19 infection. Human milk is the best form of infant nutrition providing significant protection against many illnesses for term and preterm infants. The impact of a pandemic on breastfeeding is unknown. This study seeks to address this public health issue. Breastmilk will be collected from mothers positive for COVID-19. Samples will be analyzed for the COVID-19 virus specific nucleic acid and antibody in real-time and results will be immediately disseminated to relevant organizations to inform local, national and international guidelines surrounding breastfeeding to protect the health of infants.
Description: To describe the presence of SARS-CoV-2 nucleic acid in human milk samples collected from mothers positive for COVID-19
Measure: Presence of SARS-CoV-2 in breastmilk Time: 2-6 monthsDescription: To describe the presence of SARS-CoV-2 antibody in human milk samples collected from mothers positive for COVID-19
Measure: SARS-CoV-2 antibody in breastmilk Time: 2-6 monthsThe Model School Pediatric Health Initiative arose out of concern about health access inequities and disparities among some of Toronto's most vulnerable children living in our inner-city neighborhoods. It is well documented that illness, emotional difficulties and self-esteem impacts a variety of educational markers including school attendance and performance. Providing health care in schools may be the most direct and efficient way to ensure that all children have access to the care they need including diagnosis, management and follow up of multiple health and school related concerns. American research has demonstrated that inner city children who had access to an elementary school-based health clinic (SBHC) had less difficulty receiving treatment for illnesses and injuries, immunizations, and physical examinations. In addition, rates of enrolment and utilization of elementary SBHCs are higher in those children who traditionally have poorer access to health care. Given the vast differences in the Canadian and American health systems it is important to evaluate SBHCs in Canada before long-term implementation. The objective of this study is to collect data including demographic characteristics and clinical features of students attending a SHBC at five selected sites in Toronto. In light of the COVID-19 pandemic, the research team is additionally interested in asking about families' experiences with the pandemic and school closures. It is hypothesized, that these vulnerable children who come from lower income families and/or are newcomers to Canada attending these SHBCs, are likely to experience more mental health symptoms with the heightened uncertainty surrounding the COVID-19 pandemic. This study will be a prospective chart review design. A COVID-19 questionnaire will be constructed and administered online at three time points: baseline, 6 months upon completion of the baseline questionnaire, and 12 months upon completion of the baseline questionnaire.
Description: Survey question asking whether you or any of your family developed COVID-19 symptoms, to select the symptoms that apply, and to indicate whether you or anyone in your family tested positive for COVID-19.
Measure: Direct Experience with COVID-19 virus Time: baseline to 12 monthsDescription: Survey question asking the participant to identify and describe whether their family had a positive and/or negative experience resulting from the COVID-19 crisis. Has the quality of the relationship with the child attending SBHC changed.
Measure: Family's overall experience with COVID-19 pandemic Time: baseline to 12 monthsDescription: Identify which of the listed options relating to a child's health were experienced during the pandemic. Also identify whether any of the listed health or education services were not accessed during the pandemic. How difficult has cancellations during the pandemic been for the child.
Measure: Child's experience with cancellations and access to services Time: baseline to 12 monthsDescription: Survey questions asking to what degree has the listed situations bothered the caregiver. To what degree do you (the caregiver) agree with the listed situations during the pandemic. Have you (the caregiver) been unemployed due to the pandemic and have/had trouble making ends meet. Was there enough groceries and other essentials during the pandemic.
Measure: Caregiver's experience during COVID-19 Time: baseline to 12 monthsDescription: The questions in this component of the survey includes rating how bothered you were about the listed options. Over the specified period of time, rate your stress level, describe the quality and duration of your sleep per night. How frequently did you use the listed options to relieve your stress.
Measure: stress or unpleasant experiences endured by the caregiver during COVID-19 Time: baseline to 12 monthsDescription: How frequent and for how long did you engage in the listed activities.
Measure: Activities the caregiver engaged in during COVID-19 Time: Baseline to 12 monthsDescription: Questions asking to what degree do you agree with the following statements describing your parenting ability over the specified period of time.
Measure: Describe the caregiver's parenting during COVID-19 Time: baseline to 12 monthsDescription: Questions asking what other childcare services were used during the pandemic. If they received child subsidy. If the child stayed home during the pandemic, and how long did they spend doing schoolwork and other activities (academic and non-academic) during COVID-19. Does the family have the resources to engage in online learning, if so what are the resources used. Describe any challenges faced with online learning.
Measure: The impact of school closure on the child Time: baseline to 12 months.Description: Questions asking to what extent do the statements provided describe the child. Identify the age group the child described is in.
Measure: Describing the child's character Time: baseline to 12 monthsDescription: Questions asking to rate the quality and quantity of the child's sleep. Describe and rate the child's eating behaviour/practices during the pandemic.
Measure: Childs daily routine Time: baseline to 12 monthsDescription: Questions asking how interested the child is about COVID-19, how often are they asking/reading about COVID-19. How hopeful is the child about COVID-19 ending.
Measure: Childs interest about COVID-19 Time: baseline to 12 months.Description: This question asks you to describe how frequent the child and the caregiver practiced the preventative measures to protect against COVID-19.
Measure: COVID-19 preventative measures. Time: baseline to 12 months.Description: An open ended question for the family to indicate what kind of help they would like during the pandemic
Measure: How can the SBHC help? Time: baseline to 12 months.Prospective Observational Swiss Cohort Study to Investigate Long-term Pulmonary and Extrapulmonary Effects of COVID-19.
Description: Number of patients with the long-term pulmonary complications by measuring lung function, exercise testing and radiological Imaging
Measure: Pulmonary follow-up sequelae in patients after COVID-19 Time: 36 monthsDescription: Number of patients with risk factors including comorbidities and other cofactors and correlate them to adverse outcome in patients after COVID-19
Measure: Evaluation of risk factors for adverse Outcome after COVID-19 Time: 36 monthsDescription: Compare pulmonary function measurements between mild and moderate to severe and critical COVID-19 disease
Measure: Compare the functional Pulmonary outcome of COVID-19 disease Time: 36 monthsDescription: Compare imaging measurements between mild and moderate to severe and critical COVID-19 disease
Measure: Compare the radiological Pulmonary outcome of COVID-19 disease Time: 36 monthsDescription: Compare Quality of Life questionnaires between mild and moderate to severe and critical COVID-19 disease
Measure: Quality of Life after COVID-19 Time: 36 monthsDescription: To observe and compare the physical performance after COVID-19 via the Clinical Frailty Scale between mild and moderate to severe and critical COVID-19 disease
Measure: Physical performance after COVID-19 using Clinical Frailty Scale Time: 36 monthsDescription: To observe and compare the physical performance after COVID-19 via frailty assessment tests between mild and moderate to severe and critical COVID-19 disease
Measure: Physical performance after COVID-19 using frailty assessment tests Time: 36 monthsDescription: Number of patients with changes in microbiota in response to COVID-19 by microbiota analysis of sputa, bronchoalveolar lavage and swaps
Measure: Microbiota and COVID-19 Time: 36 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports